Poseida Therapeutics IPO Presentation Deck
July 2020, 34 slides
  1. Poseida Therapeutics
  2. Related Decks
  3. IPO Presentation Decks
one therapeutics | Poseida Therapeutics
| Poseida Therapeutics
offering summary | Poseida Therapeutics
introduction to therapeutics | Poseida Therapeutics
| Poseida Therapeutics
novel approach to cell and gene therapeutics | Poseida Therapeutics
a versatile delivery system for developing car and other cell and gene therapy products | Poseida Therapeutics
cas clover proprietary hybrid gene editing platform utilizing the best of both worlds | Poseida Therapeutics
our gene delivery technology platforms are used with cas clover and other tools | Poseida Therapeutics
platform technologies fuel significant growth potential so | Poseida Therapeutics
our current cell and gene therapy pipeline | Poseida Therapeutics
oncology car programs | Poseida Therapeutics
not all cells are created equally | Poseida Therapeutics
car product candidates can potentially address the limitations of current competitor therapies | Poseida Therapeutics
learning from autologous but focused on and beyond | Poseida Therapeutics
our goal for all patients observing clinical evidence of benefit | Poseida Therapeutics
fully off the shelf car solution | Poseida Therapeutics
our booster molecule technology potential to overcome the tax common to other car approaches | Poseida Therapeutics
our booster molecule technology in action bee | Poseida Therapeutics
| Poseida Therapeutics
demonstrates tumor control and durability in a challenging preclinical model | Poseida Therapeutics
is a key to car success in solid tumors | Poseida Therapeutics
| Poseida Therapeutics
data suggest persistence of cells | Poseida Therapeutics
program has broad potential in multiple indications | Poseida Therapeutics
car demonstrated potent activity | Poseida Therapeutics
target car product candidates | Poseida Therapeutics
a gene therapy programs | Poseida Therapeutics
we believe we hold the keys to success in gene therapy | Poseida Therapeutics
rationale of as first approach | Poseida Therapeutics
a single injection of corrected in mouse model | Poseida Therapeutics
in delivery of by | Poseida Therapeutics
how we think about growth and value | Poseida Therapeutics
| Poseida Therapeutics
See More
Poseida Therapeutics
IPO Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Allogeneic
Tumor
Cancer
Delivery
Solid tumor
Technology platform
Related decks
RenovoRx
IPO
August 2021
Enochian Biosciences
Investor Presentation
October 2022
Enochian Biosciences
Results
August 2023
Mink Therapeutics
IPO
October 2021
BioNTech
Results
March 2021
BioNTech
Results
November 2021
Erasca
Investor Presentation
August 2023
Nuvalent
Investor Presentation
August 2023
RenovoRx
IPO
August 2021
Enochian Biosciences
Investor Presentation
October 2022
Enochian Biosciences
Results
August 2023
Mink Therapeutics
IPO
October 2021
BioNTech
Results
March 2021
BioNTech
Results
November 2021
Erasca
Investor Presentation
August 2023
Nuvalent
Investor Presentation
August 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io